Kaynaklar

Bu bloğun hazırlanması sırasında referans olarak yararlandığım, gelecek yazılarımda kullanmak amacıyla kaydettiğim ve kolon kanserinin moleküler temeli ve genetik özellikleri ile ilgili olarak okunmasının yararlı olduğunu düşündüğüm temel bilgilerin bulunduğu yayınların listesini bu sayfada veriyorum. 

Kolon kanseri ve kolorektal kanser ile ilgili daha detaylı bilgi edinmek isterseniz bu makalelere göz atabilirsiniz. Zamanla konu ile ilgili yayınlanan güncel makaleler oldukça ve okuduğum yeni yayınları bu listeye ekleyerek güncelleyeceğim. İyi okumalar...

Kolon Kanseri Bloğu Referans Makaleleri

Ahlquist DA. Molecular detection of colorectal neoplasia. Gastroenterology. Haziran 2010;138(6):2127–39.

Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. Şubat 2001;158(2):527–35.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, ve diğerleri. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 20 Nisan 2009;27(12):2091–6.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, ve diğerleri. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 01 Nisan 2008;26(10):1626–34.

Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, ve diğerleri. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 01 Eylül 2008;26(25):4217–9.

Bacher JW, Flanagan LA, Smalley RL, Nassif NA, Burgart LJ, Halberg RB, ve diğerleri. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers. 2004;20(4-5):237–50.

Baker K, Zhang Y, Jin C, Jass JR. Proximal versus distal hyperplastic polyps of the colorectum: different lesions or a biological spectrum? J Clin Pathol. Ekim 2004;57(10):1089–93.

Ballestar E, Esteller M. Epigenetic gene regulation in cancer. Adv Genet. 2008;61:247–67.

Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, ve diğerleri. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 15 Ekim 2008;68(20):8541–6.

Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 01 Mart 2010;28(7):1254–61.

Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer. 2005;4(3):255–65.

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, ve diğerleri. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 15 Mart 2007;67(6):2643–8.

Bettstetter M, Dechant S, Ruemmele P, Grabowski M, Keller G, Holinski-Feder E, ve diğerleri. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res. 01 Haziran 2007;13(11):3221–8.

Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, ve diğerleri. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 15 Kasım 1998;58(22):5248–57.

Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology. Haziran 1998;114(6):1188–95.

Chittenden TW, Howe EA, Culhane AC, Sultana R, Taylor JM, Holmes C, ve diğerleri. Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. Genomics. Haziran 2008;91(6):508–11.

Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 13 Mart 2008;358(11):1160–74.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, ve diğerleri. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 22 Temmuz 2004;351(4):337–45.

Danielsen SA, Lind GE, Bjørnslett M, Meling GI, Rognum TO, Heim S, ve diğerleri. Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation- status. Hum Mutat. Kasım 2008;29(11):E252–62.

Deacu E, Mori Y, Sato F, Yin J, Olaru A, Sterian A, ve diğerleri. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Cancer Res. 01 Kasım 2004;64(21):7690–6.

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, ve diğerleri. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 23 Nisan 2007;96(8):1166–9.

Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ, ve diğerleri. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. Eylül 2004;41(9):664–8.

Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 12 Ağustos 2002;21(35):5400–13.

Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, ve diğerleri. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 23 Ağustos 1996;86(4):543–52.

Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, ve diğerleri. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 15 Eylül 2003;63(18):5738–44.

Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. Şubat 2004;4(2):143–153.

Goldstein NS. Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. Am J Clin Pathol. Ocak 2006;125(1):146–53.

Goldstein NS. Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. Am J Clin Pathol. Ocak 2006;125(1):146–53.

Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. Ekim 2008;135(4):1079–99.

Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. Haziran 2004;23(1-2):11–27.

Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, ve diğerleri. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 15 Ocak 1999;59(2):320–4.

Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, ve diğerleri. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 15 Temmuz 1998;58(14):3101–4.

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, ve diğerleri. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 05 Mayıs 2005;352(18):1851–60.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 07 Ocak 2000;100(1):57–70.

Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, ve diğerleri. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology. Ekim 2002;123(4):1109–19.

Hinoue T, Weisenberger DJ, Lange CPE, Shen H, Byun H-M, Van Den Berg D, ve diğerleri. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. Şubat 2012;22(2):271–82.

Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, ve diğerleri. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS ONE. 2009;4(12):e8357.

Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol. Aralık 2008;13(6):498–503.

Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, ve diğerleri. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. Kasım 2008;103(11):2862–70.

Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, Sontag S, ve diğerleri. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. Ocak 2007;5(1):111–7.

Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, ve diğerleri. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 20 Ekim 2009;27(30):5068–74.

Jass JR. Hyperplastic polyps and colorectal cancer: is there a link? Clin Gastroenterol Hepatol. Ocak 2004;2(1):1–8.

Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, ve diğerleri. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 01 Mart 1997;57(5):808–11.

Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, ve diğerleri. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 23 Ekim 2008;359(17):1757–65.

Li M, Chen W-D, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, ve diğerleri. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. Eylül 2009;27(9):858–63.

Lièvre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, ve diğerleri. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 15 Nisan 2006;66(8):3992–5.

Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, ve diğerleri. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 21 Temmuz 2010;102(14):1012–22.

Little MP, Vineis P, Li G. A stochastic carcinogenesis model incorporating multiple types of genomic instability fitted to colon cancer data. J Theor Biol. 21 Eylül 2008;254(2):229–38.

Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, ve diğerleri. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer. 01 Eylül 2005;104(5):952–61.

Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, ve diğerleri. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. Nisan 2006;38(4):468–73.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, ve diğerleri. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 02 Haziran 1995;268(5215):1336–8.

Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S, Kim YS. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res. 15 Aralık 2005;11(24 Pt 1):8564–9.

Miyaki M, Iijima T, Kimura J, Yasuno M, Mori T, Hayashi Y, ve diğerleri. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res. 15 Eylül 1999;59(18):4506–9.

Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009;4:343–64.

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, ve diğerleri. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE. 2008;3(11):e3698.

Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, ve diğerleri. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. Haziran 2008;10(6):534–41.

Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. Ocak 2008;10(1):13–27.

Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. Temmuz 2007;9(3):305–14.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, ve diğerleri. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol. 20 Eylül 2009;27(27):4591–8.

Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, ve diğerleri. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 20 Mart 2009;27(9):1477–84.

Parsons DW, Wang T-L, Samuels Y, Bardelli A, Cummins JM, DeLong L, ve diğerleri. Colorectal cancer: mutations in a signalling pathway. Nature. 11 Ağustos 2005;436(7052):792.

Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer. Eylül 2005;41(14):2060–70.

Pritchard CC, Grady WM. Colorectal Cancer Molecular Biology Moves Into Clinical Practice. Gut. Ocak 2011;60(1):116–29.

Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 29 Ağustos 2002;418(6901):934.

Rashid A, Shen L, Morris JS, Issa JP, Hamilton SR. CpG island methylation in colorectal adenomas. Am J Pathol. Eylül 2001;159(3):1129–35.

Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, ve diğerleri. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer. 2008;8:234.

Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, ve diğerleri. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 10 Aralık 2009;27(35):5931–7.

Rodriguez J, Frigola J, Vendrell E, Risques R-A, Fraga MF, Morales C, ve diğerleri. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 01 Eylül 2006;66(17):8462–9468.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, ve diğerleri. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 20 Ocak 2010;28(3):466–74.

Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schönfels W, ve diğerleri. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer. Nisan 2011;18(2):265–76.

Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, ve diğerleri. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. Eylül 2005;129(3):837–45.

Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 01 Nisan 1999;59(7):1442–4.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, ve diğerleri. High frequency of mutations of the PIK3CA gene in human cancers. Science. 23 Nisan 2004;304(5670):554.

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, ve diğerleri. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 01 Mart 2009;69(5):1851–7.

Sawan C, Herceg Z. Histone modifications and cancer. Adv Genet. 2010;70:57–85.

Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut. Haziran 2010;59(6):794–9.

Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. Ocak 2010;31(1):27–36.

Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, ve diğerleri. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 20 Kasım 2007;104(47):18654–9.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 07 Ekim 2009;101(19):1308–24.

Silver A, Sengupta N, Propper D, Wilson P, Hagemann T, Patel A, ve diğerleri. A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int J Cancer. 01 Mart 2012;130(5):1082–92.

Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. Nisan 2010;60(2):99–119.

South CD, Yearsley M, Martin E, Arnold M, Frankel W, Hampel H. Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genet Med. Kasım 2009;11(11):812–7.

Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 06 Mart 1998;92(5):645–56.

Tanaka T, Watanabe T, Kazama Y, Tanaka J, Kanazawa T, Kazama S, ve diğerleri. Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer--a study matched for tumor depth and pathology. J Surg Oncol. 01 Ocak 2008;97(1):69–73.

Ting AH, McGarvey KM, Baylin SB. The cancer epigenome--components and functional correlates. Genes Dev. 01 Aralık 2006;20(23):3215–31.

Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 02 Temmuz 2009;361(1):98–9.

Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 20 Temmuz 1999;96(15):8681–6.

Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, ve diğerleri. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 02 Nisan 2009;360(14):1408–17.

Van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol. 01 Nisan 2011;29(10):1382–91.

Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. Aralık 2008;7(12):979–87.

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, ve diğerleri. Genetic alterations during colorectal-tumor development. N Engl J Med. 01 Eylül 1988;319(9):525–32.

Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut. Temmuz 2008;57(7):941–50.

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. Temmuz 2009;9(7):489–99.

Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, ve diğerleri. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 01 Eylül 2003;63(17):5209–12.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, ve diğerleri. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. Temmuz 2006;38(7):787–93.

Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 18 Eylül 2008;27(41):5497–510.

Zauber P, Sabbath-Solitare M, Marotta SP, Bishop DT. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. MP, Mol Pathol. Haziran 2003;56(3):137–40.

Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. Temmuz 2008;10(4):301–7.

Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, ve diğerleri. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer. 01 Aralık 2010;127(11):2569–75.